Summary of the live webcast held on March 4, 2024, providing an update on AB Science development
07/03/2024 – AB Science is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development
Two financial analysis firms initiate coverage of AB Science
06/03/2024 – AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
AB Science webcast of March 4, 2024
04/03/2024 – Presentation of the AB Science webcast held on March 4, 2024
Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
01/03/2024 – AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALS
26/02/2024 – AB Science today announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26/01/2024 – AB Science announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding Issues at D195 of the procedure, instead of addressing these issues through the Oral Explanation
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
15/01/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis with its lead compound masitinib, based on findings from study AB06006
AB Science webcast – Masitinib in Sickle Cell Disease
30/11/2023 – Presentation of the Masitinib in Sickle Cell Disease webcast
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease
28/11/2023 – AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
27/11/2023 – AB Science announces today that a new clinical development program for masitinib in sickle cell disease is among the 19 winning projects to be funded under the sixth call for “Hospital-University Research in Health” (Recherche Hospitalo-Universitaire en santé) projects, which part of the Future Investments Program